Download PDF
Dtsch Med Wochenschr 2019; 144(14): 982-989
DOI: 10.1055/a-0832-3393
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund

Woran ist zu denken? Was ist zu tun?Monoclonal Gammopathy Of Unknown Significance – A Common Incidental FindingWhat is to be thought of? What has to be done?
Aneta Schieferdecker
,
Mascha Binder
,
Katja Weisel
,
Carsten Bokemeyer
Further Information

Publication History

Publication Date:
16 July 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Monoclonal gammopathy of unclear significance (MGUS) is detected at high frequency in a variety of disciplines as an incidental finding. MGUS can be associated with non-malignant diseases, but it also can be a precursor of malignant lymphoproliferative disorders (multiple myeloma, Waldenstroem’s disease, other non-Hodgkin’s lymphoma, light chain (AL) – amyloidosis). However, many of these patients remain asymptomatic throughout their lives. Screening is performed by serum protein electrophoresis, immunofixation and determination of quantitative immunoglobulins and free light chains in serum. Currently, general population screening is not recommended. There are three subtypes with different rates and types of progression: IgM-MGUS, non-IgM-MGUS, and light-chain MGUS. The scope of further diagnostics and follow-up is based on the clinical findings and risk stratification (monoclonal protein in serum < or ≥ 15 g/l and normal or abnormal free light chain ratio in serum). If paraprotein-associated disease is detected, gammopathy is of clinical significance and should not be referred to as MGUS.

Die monoklonale Gammopathie unklarer Signifikanz (MGUS) wird mit hoher Frequenz in den verschiedensten Fachdisziplinen als Zufallsbefund detektiert. Die hohe Prävalenz, das Risiko der Progression zu lymphoproliferativen Neoplasien sowie die Assoziation mit einigen nicht malignen Erkrankungen verdeutlichen die große klinische Bedeutung der MGUS. Der Beitrag bietet einen Überblick über notwendige Diagnostik und Verlaufskontrollen.

Schlüsselwörter

Monoklonale Gammopathie unklarer Signifikanz - MGUS - Paraproteinämie - klonales Protein - M-Protein

Key words

monoclonal gammopathy of unknown significance - MGUS - paraproteinemia - clonal protein - M protein
 

  • Literatur

  • 1 Landgren O, Kyle RA, Pfeiffer RM. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417
    CrossrefPubMedGoogle Scholar
  • 2 Weiss BM, Hebreo J, Cordaro DV. et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. Journal of clinical oncology: J Am Soc Clin Oncol 2014; 32: 2699-2704
    PubMedGoogle Scholar
  • 3 Bida JP, Kyle RA, Therneau TM. et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009; 84: 685-693
    CrossrefPubMedGoogle Scholar
  • 4 Landgren O, Graubard BI, Kumar S. et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10 – 49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J 2017; 7 (10) e618
    CrossrefPubMedGoogle Scholar
  • 5 Kyle RA, Therneau TM, Rajkumar SV. et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369
    CrossrefPubMedGoogle Scholar
  • 6 Dispenzieri A, Katzmann JA, Kyle RA. et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375: 1721-1728
    CrossrefPubMedGoogle Scholar
  • 7 Kyle RA, Therneau TM, Rajkumar SV. et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-569
    CrossrefPubMedGoogle Scholar
  • 8 Turesson I, Kovalchik SA, Pfeiffer RM. et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 2014; 123: 338-345
    CrossrefPubMedGoogle Scholar
  • 9 Kyle RA, Gertz MA, Witzig TE. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33
    CrossrefPubMedGoogle Scholar
  • 10 Kyle RA, Larson DR, Therneau TM. et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2018; 378: 241-249
    CrossrefPubMedGoogle Scholar
  • 11 Doyle LMGJ, Farnen JP, Wright LJ. et al. Determining why and which clinicians order serum protein electrophoresis (SPEP), subsequent diagnoses based on indications, and clinical significance of routine follow-up: a study of patients with monoclonal gammopathy of undetermined significance (MGUS). Blood 2009; 114: 4883
    PubMedGoogle Scholar
  • 12 Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009; 30: 105-111
    PubMedGoogle Scholar
  • 13 Hutchison CA, Harding S, Hewins P. et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684-1690
    CrossrefPubMedGoogle Scholar
  • 14 Rossi A, Voigtlaender M, Janjetovic S. et al. Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood cancer J 2017; 7: e537
    CrossrefPubMedGoogle Scholar
  • 15 Xu L, Hunter ZR, Tsakmaklis N. et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia. Brit J Haematol 2016; 172: 735-744
    CrossrefPubMedGoogle Scholar
  • 16 Mangiacavalli S, Cocito F, Pochintesta L. et al. Monoclonal gammopathy of undetermined significance: a new proposal of workup. Eur J Haematol 2013; 91: 356-360
    PubMedGoogle Scholar
  • 17 Rajkumar SV, Kyle RA, Therneau TM. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-817
    CrossrefPubMedGoogle Scholar
  • 18 Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood 2018; 131: 163-173
    CrossrefPubMedGoogle Scholar
  • 19 Kyle RA, Durie BG, Rajkumar SV. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127
    CrossrefPubMedGoogle Scholar
  • 20 van de Donk NW, Palumbo A, Johnsen HE. et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica 2014; 99: 984-996
    CrossrefPubMedGoogle Scholar
  • 21 Milani P, Merlini G, Palladini G. Light Chain Amyloidosis. Mediterr J Hematol Infect Dis 2018; 10: e2018022
    CrossrefPubMedGoogle Scholar
  • 22 Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clinical lymphoma, myeloma & leukemia 2015; 15: 177-186 e174
    CrossrefPubMedGoogle Scholar
  • 23 Go RS, Sangaralingham LR, Habermann EB. Estimating the Risk of Progression of Monoclonal Gammopathy of Undetermined Significance into Lymphoplasmacytic Malignancies in the United States: Determining Demographic Differences Using a National Dataset. Blood 2016; 128: 843
    CrossrefPubMedGoogle Scholar
  • 24 Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clinic Proc 2017; 92: 838-850
    CrossrefPubMedGoogle Scholar
  • 25 Correia SO, Santos S, Malheiro J. et al. Monoclonal gammopathy of renal significance: Diagnostic workup. World J Nephrol 2017; 6: 72-78
    PubMedGoogle Scholar